Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Our first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase. Today, we are actively looking for funding to finance a Clinical Phase I/Phase II trial in humans.